Data protection Impressum

Biotech

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (January 2024)

30 January 2024

Onward Therapeutics’ move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.

Onward Therapeutics enters clinical phase with innovative cancer immunotherapy

30 January 2024

This CHF 18 million initiative focuses on developing artificial intelligence-guided neuromodulation therapies to treat neurologic and mental health disorders.

Wyss Center launches Lighthouse Partnership with key institutions from Western Switzerland

29 January 2024

Founded in 2016 in Argentina, Stämm, now boasting a robust team of over 200 in Buenos Aires and San Francisco, specializes in harnessing nature-inspired, data-driven solutions to revolutionize bioprocessing.

Biomanufacturing innovator Stämm opens its European R&D facility in Monthey

25 January 2024

BioLizard’s move to Lausanne reflects its growing international presence and dedication to serving the Swiss biotech industry.

Bioinformatics specialist BioLizard opens a new office at the Biopôle in Lausanne

24 January 2024

Nicolas Collin, Co-Founder and CEO of the Vaccine Formulation Institute (VFI), discusses the innovative approach and global impact of their work in developing high-quality, accessible adjuvants for vaccines and why Geneva was chosen as the ideal location for VFI's impactful work.

Why the Vaccine Formulation Institute chose Western Switzerland

23 January 2024

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Cellestia Biotech receives CHF 2 million for its pioneering GvHD prevention therapy

23 January 2024

STALICLA has developed the first neurodevelopmental disorder-specific precision medicine platform with an initial application in autism spectrum disorder (ASD).

STALICLA secures USD 17.4 million to propel neuro precision medicine

22 January 2024

For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation with economic growth.

The remarkable chemical-pharmaceutical industry in the canton of Valais

This funding and partnership with the ADDF place GliaPharm at the forefront of developing effective treatments for Alzheimer’s, offering new hope in the fight against this challenging neurodegenerative disease.

GliaPharm receives USD 4.2 million to propel Alzheimer’s treatment development

20 December 2023

1 … 6 7 8 9 10 11 12 13 14 … 22